On the analysis of viral load endpoints in HIV vaccine trials

Statistics in Medicine

Volumn 22, Issue 14, 2003, Pages 2281-2298

  Hudgens, Michael G ^a   Hoering, Antje ^b   Self, Steven G ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Insightful Corporation   (United States)

Author keywords

Bootstrap; Causal inference; HIV vaccine trials; Hypothesis testing; Selection bias; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; INFECTION SENSITIVITY; OUTCOMES RESEARCH; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS LOAD;

AIDS VACCINES; CLINICAL TRIALS; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 0042490767     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1394     Document Type: Article

References (45)

1. Francis DP, Gregory T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, Kitayaporn D, Pitisuttitham P, Matthews T, Schwartz DH, Berman PW. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Research and Human Retroviruses 1998; 14(suppl 3):S325-S331.
2. Francis DP. The AIDSVAX B/B phase III efficacy trial in North American and the Netherlands. In AIDS Vaccine 2001, Philadelphia, 2001, Abstract No. S10.
3. Pitisuttithum P. Thailand's success in moving to the first phase III HIV vaccine efficacy trial in a developing country. In AIDS Vaccine 2001, Philadelphia, 2001, Abstract No. S11.
4. Birx DL. The US Army's plans for phase III HIV vaccine trials. In AIDS Vaccine 2001, Philadelphia, 2001, Abstract No. S13.
5. Cohen J. Disappointing data scuttle plans for large-scale AIDS vaccine trial. Science 2002; 295:1616-1617.
6. Halloran ME, Struchiner CJ, Longini IM. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. American Journal of Epidemiology 1997; 146:789-803.
7. Longini IM, Hudgens MG, Halloran ME. Estimation of vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines with partner augmentation. In The Quantitative Evaluation of HIV Prevention Programs, Kaplan E, Brookmeyer R (eds). Yale University Press: New Haven, 2002; 241-259.
8. Clements-Manni ML. Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Research and Human Retroviruses 1998; 14(suppl 3):S197-203.
9. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SL, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, Robinson HL. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292(5514):69-74.
10. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka, GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-492.
11. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. American Journal of Tropical Medicine and Hygiene 1989; 40:444-451.
12. Nabel GJ. Challenges and opportunities for development of an AIDS vaccine. Nature 2001; 410:1002-1007.
13. Burke DS. Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk? Perspectives in Biology and Medicine 1992; 35(4):511-530.
14. Mascola JR, Mathieson BJ, Zack PM, Walker MC, Halstead SB, Burke DS. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Research and Human Retroviruses 1993; 9(12):1175-1184.
15. Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, Mack ME, Davidson BL, Kapikian AZ, for the United States Rotavirus Vaccine Efficacy Group. Safety and efficacy of high-doserhesus-human reassortant rotavirus vaccines - report of the national multicenter trial. Pediatrics 1996; 97:7-13.
16. Lanata CF, Black RE, Flores J, Lazo F, Butron B, Linares A, Huapaya A, Ventura G, Gil A, Kapikian A.Z. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru. Vaccine 1996; 14(3):237-243.
17. Longini LM, Datta S, Halloran ME. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996; 13:440-447.
18. Mellors JW, Kingsley LA, Rinaldo Jr., CR, Todd JA, Kokka RP, Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of Internal Medicine 1995; 122:573-579.
19. Katzenstein TL, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, Gerstoft J. Longitudinal serum HPV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996; 10(2):167-173.
20. Pedersen C, Katzenstein T, Nielsen C, Lundgren JD, Gerstoft G. Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: relation to CD4 cell count and clinical course of primary infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997; 16:93-99.
21. Regoes RR, Staprans SI, Feinberg MB, Bonhoeffer S. Contribution of peaks of virus load to simian immunodeficiency virus pathogenesis. Journal of Virology 2002; 76(5):2573-2578.
22. Mellors JW, Gupta Jr., CR, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1124-1125.
23. Smith SM, Holland B, Russo C, Dailey PJ, Marx PA, Connor RI. Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression. AIDS Research and Human Retroviruses 1999; 15:1691-1701.
24. Watson A, Ranchalis J, Travis B, McClure J, Sutton W, Johnson PR, Hu SL, Haigwood NL. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. Journal of Virology 1997; 71:284-290.
25. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M, Elkins WR, Alvord WG, Montefiori DC, Moss B, Lifson JD. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. Journal of Virology 1996; 70:3741-3752.
26. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RE. Viral load and heterosexual transmission of human immunodeficiency virus type 1. New England Journal of Medicine 2000; 342:921-929.
27. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Annals of Internal Medicine 1996; 125:605-613.
28. Fleming TR. Surrogate markers in AIDS and cancer trials (disc: P1437-1440). Statistics in Medicine 1994; 13:1423-1435.
29. Rubin DB. Bayesian inference for causal effects: The role of randomization. Annals of Statistics 1978; 6: 34-58.
30. Rubin DB. Comment on Causal inference without counterfactuals. Journal of the American Statistical Association 2000; 95:435-437.
31. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics 2002; 58:21-29.
32. Halloran ME, Struchiner CJ. Causal inference in infectious diseases. Epidemiology 1995; 6:142-151.
33. Pepe MS, Fleming TR. Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. Biometrics 1989; 45:497-507.
34. Lyles RH, Lyles CM, Taylor DJ. Random regression models for human immunodeficiency virus ribonucleic acid data subject to left censoring and informative drop-outs. Applied Statistics 2000; 49(4):485-497.
35. Hughes MD. Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials. Statistics in Medicine 2000; 19(23):3171-3191.
36. Davison AC, Hinkley DV. Bootstrap Methods and Their Application. Cambridge University Press: United Kingdom 1997.
37. Vardi Y. Empirical distributions in selection bias models (com: P204-205). Annals of Statistics 1985; 13: 178-203.
38. Brambilla D, Reichelderfer PS, Bremer JW, Shapiro DE, Hershow RC, Katzenstein DA, Hammer SM, Jackson B, Collier AC, Sperling RS, Fowler MG, Coombs RW. The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. AIDS 1999; 13:2269-2279.
39. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Annals of Internal Medicine 1996; 125:257-264.
40. Schacker T, Hughes J, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Annals of Internal Medicine 1998; 128:613-620.
41. Rida WN, Fast P, Hoff R, Fleming TR. Intermediate-sized trials for the evaluation of HIV vaccine candidates: a workshop summary. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1997; 16:195-203.
42. Chang MN, Guess HA, Heyse JF. Reduction in burden of illness: a new efficacy measure for prevention trials. Statistics in Medicine 1994; 13:1807-1814.
43. Lachenbruch PA. Estimation of parameters of the Poisson with excess zeroes and negative binomial with excess zeroes distributions. Biometrical Journal. Journal of Mathematical Methods in Biosciences 1975; 17:339-344.
44. Lachenbruch PA. Analysis of data with clumping at zero. Biometrical Journal. Journal of Mathematical Methods in Biosciences 1976;18:351-356.
45. Leroy V, Karon JM, Alioum A, Ekpini ER, Meda N, Wiktor SZ, Msellate P, Hudgens MG, Greenberg AE, Dabis F. Maternal immunodeficiency reduces the efficacy of a short zidovudine maternal regimen to prevent mother-to-child transmission of HIV-1 in West Africa: a pooled analysis of two randomised clinical trials. AIDS 2002; 16:631-641.